Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.
Women with hormone receptor-positive, HER2-negative metastatic breast cancer derive a significant progression-free survival benefit from the addition of alisertib to paclitaxel, indicate phase 2 trial findings.
The majority of patients with cancer and their physicians report a preference for in-person visits rather than telemedicine consultations, suggest results of a survey carried out at the start of the COVID-19 pandemic.
The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.
Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.
Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.
Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.
The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.